Compare DexCom, Inc. (DXCM) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Tyson Foods, Inc. — how do they compare? DexCom, Inc. trades at $78.01 (market cap $28.06B), while Tyson Foods, Inc. trades at $58.1 (market cap $20.24B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Tyson Foods, Inc. pays a 3.55% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | TSN | |
|---|---|---|
Market Cap | $28.06B | $20.24B |
Sector | Health | Consumer Staples |
52-Week High | $89.53 | $68.75 |
52-Week Low | $54.84 | $50.72 |
Enterprise Value | $27.03B | $27.82B |
Dividend Yield | — | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Tyson Foods (TSN) trades at $57.48, down 0.76% on the day, with a bearish technical signal but strong analyst support. The stock shows mixed fundamentals with a low P/S ratio of 0.37 and P/B of 1.12, but elevated P/E of 45.25 reflects thin net margins of 0.81%. Recent earnings have been inconsistent, beating estimates in Q3 2025 and Q1 2026 but missing in Q4 2025. The company maintains steady dividends and is focusing on growth in prepared foods.
The outlook presents a value opportunity with a consensus price target of $68.80 offering ~20% upside, supported by 50% analyst buy ratings. However, risks include volatile earnings, compressed profit margins, and significant debt load. The bearish technical picture suggests near-term pressure, while strategic initiatives in value-added products could drive long-term recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
